Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Provided By PR Newswire
Last update: May 27, 2025
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026
Read more at prnewswire.com187.38
+28.42 (+17.88%)
1.38
-0.06 (-4.17%)
Find more stocks in the Stock Screener
IQV Latest News and Analysis
